Clinical Trials & Research

Leading Research. Promising Drug Trials.

Over the past 20 years, New York Oncology Hematology patients have participated in clinical drug trials leading to FDA approval of 41 new cancer therapies. With the largest, most comprehensive clinical research operation in the region, NYOH is constantly offering eligible patients opportunities to join new trials.

View Open Trials

About Clinical Research

Clinical trials are human research studies, conducted with volunteers who participate in the testing of new therapies. The purpose is finding new, more effective cancer treatment. NYOH is the largest organization in the area that participates in Phase I/II and III trials, including those for all major solid tumor types, hematologic malignancies and supportive care.

Our Clinical Research Mission

NYOH is committed to delivering high quality, ethically conducted, world class clinical research trials and superior research support services to promote the scientific advancement of cancer care as we offer our patients access to breakthrough treatments close to home. 

The NYOH Clinical Research Program

Through our affiliation with The US Oncology Network, one of the largest and most reputable community-based research networks in the world, NYOH has access to some of the most promising new trials being offered. We also participate in National Cancer Institute (NCI) sponsored research.

At New York Oncology Hematology, we are proud of our role in the research and development of vital new cancer therapies. And we are deeply committed to bringing clinical trials to our community, offering patients an opportunity to help shape the future of cancer treatment, while benefitting from the very latest in clinical trials.

Over the past two decades, NYOH patients and physicians have participated in clinical drug trials leading to FDA approval of 39 new cancer therapies:

Abraxane
Afinitor
Alimta
Aranesp
Arimidex
Aromasin
Avastin
Camptosar
Doxil
Eloxatin
Erbitux
Faslodex
Gazyva
Gemzar
Halaven
Herceptin
Hycamtin
Inlyta
Iressa

Ixempra
Kadcyla
Neulasta
Neupogen
Nexavar
Provenge
Rituxan
Sprycel
Sutent
Tarceva
Tasigna
Taxotere 

Tencentriq
Tykerb
Vectibix
Velcade
Vidaza
Votrient
Xeloda
Zometa

To learn more about a study or to refer an eligible patient, please contact:

Amy Zuchelkowski
Clinical Research Manager

(518) 489-3612 ext. 1045

Email